Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

BIOMARIN PHARMACEUTICAL INC Form 4 September 05, 2013

Check this box if no longer subject to Section 16.									3235-0287 January 31, 2005 verage	
1(b). (Print or Type Responses)										
	ddress of Reporting I AN DANIEL K	Symbo BION	2. Issuer Name and Ticker or Trading Symbol BIOMARIN PHARMACEUTICAL INC [BMRN]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) (First) (Middle) 105 DIGITAL DRIVE			3. Date of Earliest Transaction (Month/Day/Year) 09/04/2013				Director 10% Owner Officer (give title Other (specify below) below) EVP, Chief Financial Officer			
(Street) NOVATO, CA 94949			4. If Amendment, Date Original Filed(Month/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
		(Person			
(City)	(State)	(Zip) T	able I - Non-I	Derivative	Secur	ities Acq	uired, Disposed of		-	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, any (Month/Day/Yea	Code r) (Instr. 8)	4. Securi on(A) or Di (Instr. 3, Amount	ispose 4 and (A) or	d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common Stock	09/04/2013 <u>(1)</u>	09/04/2013	М	9,000	A	\$ 39.06	46,950	D		
Common Stock	09/04/2013 <u>(1)</u>	09/04/2013	S	9,000	D	\$ 69	37,950	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number onof Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 39.06	09/04/2013 <u>(1)</u>	09/04/2013	М	9,000	11/29/2012 <u>(2)</u>	05/28/2022	Common Stock	9,000

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
SPIEGELMAN DANIEL K 105 DIGITAL DRIVE NOVATO, CA 94949			EVP, Chief Financial Officer				
Signatures							
/s/ Laura Randall Woodhead, Attorney-in-Fact		(09/05/2013				
<u>**</u> Signature of Reporting Perso	n		Date				
Evaluation of Responses:							

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Transaction made pursuant to a Rule 10b5-1 plan executed on May 10, 2013.

(2) Option grant vests 6/48ths on November 29, 2012 and 1/48th on the 29th day of every month thereafter.

(3) Reflects the number of stock options that remain outstanding from this specific stock option grant following the reported transaction.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.